Sarah Nikiforow

11.3k total citations · 1 hit paper
152 papers, 3.4k citations indexed

About

Sarah Nikiforow is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Sarah Nikiforow has authored 152 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Hematology, 77 papers in Oncology and 62 papers in Immunology. Recurrent topics in Sarah Nikiforow's work include Hematopoietic Stem Cell Transplantation (58 papers), CAR-T cell therapy research (46 papers) and Immune Cell Function and Interaction (45 papers). Sarah Nikiforow is often cited by papers focused on Hematopoietic Stem Cell Transplantation (58 papers), CAR-T cell therapy research (46 papers) and Immune Cell Function and Interaction (45 papers). Sarah Nikiforow collaborates with scholars based in United States, France and Canada. Sarah Nikiforow's co-authors include Corey Cutler, Joseph H. Antin, Robert J. Soiffer, George Miller, Jerome Ritz, John Koreth, Vincent T. Ho, Edwin P. Alyea, Haesook T. Kim and Philippe Armand and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Sarah Nikiforow

142 papers receiving 3.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

2024 210 citations Matthew J. Frigault, Sarah Nikiforow et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Nikiforow United States	31	1.8k	1.4k	1.2k	509	463	152	3.4k
Marie Bleakley United States	27	2.0k 1.1×	1.5k 1.1×	885 0.8×	423 0.8×	612 1.3×	55	3.4k
Anita Schmitt Germany	33	1.7k 1.0×	1.6k 1.1×	977 0.8×	290 0.6×	1.0k 2.2×	142	3.5k
Joseph P. McGuirk United States	30	1.7k 0.9×	728 0.5×	1.5k 1.3×	244 0.5×	1.1k 2.3×	274	3.7k
Carolyn A. Keever-Taylor United States	25	1.1k 0.6×	1.3k 0.9×	1.3k 1.1×	206 0.4×	309 0.7×	79	2.5k
Mikhail Roshal United States	27	2.3k 1.3×	862 0.6×	1.2k 1.1×	239 0.5×	1.4k 3.1×	103	4.3k
Markus Wiesneth Germany	31	802 0.4×	903 0.6×	982 0.8×	415 0.8×	494 1.1×	118	2.7k
Justin Kline United States	33	2.8k 1.6×	3.6k 2.5×	938 0.8×	223 0.4×	1.2k 2.5×	146	5.5k
Alice Bertaina Italy	35	996 0.6×	1.8k 1.3×	1.5k 1.3×	399 0.8×	628 1.4×	141	3.6k
Scott R. Solomon United States	34	1.8k 1.0×	1.2k 0.9×	2.6k 2.2×	260 0.5×	807 1.7×	197	4.2k
Javier Briones Spain	35	1.9k 1.0×	1.7k 1.2×	1.0k 0.9×	296 0.6×	831 1.8×	161	4.5k

Countries citing papers authored by Sarah Nikiforow

Since Specialization

Citations

This map shows the geographic impact of Sarah Nikiforow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Nikiforow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Nikiforow more than expected).

Fields of papers citing papers by Sarah Nikiforow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Nikiforow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Nikiforow. The network helps show where Sarah Nikiforow may publish in the future.

Co-authorship network of co-authors of Sarah Nikiforow

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Nikiforow. A scholar is included among the top collaborators of Sarah Nikiforow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Nikiforow. Sarah Nikiforow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghobadi, Armin, Robert A. Baiocchi, Sridhar Chaganti, et al.. (2025). Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus–Driven Posttransplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy. Transplantation and Cellular Therapy. 31(2). S506–S507.

Hsu, Joanne I., Sarah Nikiforow, & Nancy Berliner. (2025). Hemophagocytic lymphohistiocytosis in adults. Blood. 147(10). 1037–1047.

John, Samuel, Kevin J. Curran, Amy K. Keating, et al.. (2025). Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Advances. 9(20). 5249–5262.

Locke, Frederick L., Sarah Nikiforow, Matthew J. Frigault, et al.. (2025). Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies. Transplantation and Cellular Therapy.

Kim, Haesook T., Vincent T. Ho, Sarah Nikiforow, et al.. (2024). Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis. Transplantation and Cellular Therapy. 30(7). 687.e1–687.e13. 3 indexed citations

Nikiforow, Sarah, Michael K. Mansour, Zhen‐Huan Hu, et al.. (2024). Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. UNC Libraries.

Nikiforow, Sarah, Jennifer Whangbo, Ran Reshef, et al.. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances. 8(12). 3001–3012. 8 indexed citations

Maurer, Katie, Vincent T. Ho, Corey Cutler, et al.. (2023). Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Advances. 7(15). 3903–3915. 14 indexed citations

Maurer, Katie, Haesook T. Kim, Deborah Liney, et al.. (2023). Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells. Blood Advances. 7(11). 2431–2435. 7 indexed citations

10.

Johnson, P. Connor, Haesook T. Kim, Meghan E. Sise, et al.. (2023). Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 29(7). 455.e1–455.e9. 3 indexed citations

11.

Oluwole, Olalekan O., Bhagirathbhai Dholaria, Tristan Knight, et al.. (2023). Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 30(2). 131–142. 17 indexed citations

12.

Shapiro, Roman M., Haesook T. Kim, Michela Ansuinelli, et al.. (2023). Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Advances. 7(15). 4080–4088. 2 indexed citations

13.

Ikegawa, Shuntaro, Haesook T. Kim, Gordon J. Freeman, et al.. (2022). Low Dose IL-2 Therapy in Patients with Chronic Gvhd Induces PD-1+treg That Are Highly Activated, Immune Suppressive, and Proapoptotic. Transplantation and Cellular Therapy. 28(3). S59–S60. 1 indexed citations

14.

Maurer, Katie, Haesook T. Kim, Utkarsh Acharya, et al.. (2021). COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances. 5(3). 861–871. 24 indexed citations

15.

Maurer, Katie, Haesook T. Kim, Carol Reynolds, et al.. (2021). Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Advances. 5(23). 5140–5149. 20 indexed citations

16.

Kim, Haesook T., Lindsey E. Roeker, Corey Cutler, et al.. (2019). Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 26(3). 529–539. 16 indexed citations

17.

Jaglowski, Samantha, Zhen‐Huan Hu, Yiyun Zhang, et al.. (2019). Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood. 134(Supplement_1). 766–766. 62 indexed citations

18.

Prockop, Susan E., Robert A. Baiocchi, Nancy Bunin, et al.. (2018). Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder. Biology of Blood and Marrow Transplantation. 24(3). S41–S42. 6 indexed citations

19.

Esrick, Erica B., John Manis, Heather Daley, et al.. (2018). Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Advances. 2(19). 2505–2512. 59 indexed citations

20.

Kamihara, Yusuke, Édouard Forcade, John Koreth, et al.. (2017). Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells and Suppresses Circulating T Follicular Helper Cells in Patients with Chronic Gvhd. Blood. 130(Suppl_1). 74–74. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact